Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468984 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
A Phase 3 study of Myelofibrosis (MF), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT04468984 is a Phase 3 study of Myelofibrosis (MF) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 330 participants, below the 931-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04468984, a Phase 3 study of Myelofibrosis (MF), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. In Arm C, participants will receive navitoclax. Adult participants with a diagnosis of MF that came back or did not get better after earlier treatment will be enrolled. Approximately 330 participants will be enrolled in approximately 322 sites across the world. In Arm A, participants will receive navitoclax tablet by mouth once daily with by mouth ruxolitinib tablet twice daily. In Arm B, participants will receive the BAT available to the investigator. In Arm C, participants will receive navitoclax tablet by mouth once daily. Participants will receive the study drug until they experience no benefit (determined by the investigator), participants cannot tolerate the study drugs, or participants withdraw consent. The approximate treatment duration is about 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Navitoclax
- DRUG Best Available Therapy (BAT)
Study Locations (20)
California
- City of Hope /ID# 218996 - Duarte
- Providence - St. Jude Medical Center /ID# 271382 - Fullerton
- Moores Cancer Center /ID# 271596 - La Jolla
- Moores Cancer Center at UC San Diego /ID# 219009 - La Jolla
- Long Beach Memorial Medical Ct /ID# 224542 - Long Beach
- Icri /Id# 221967 - Whittier
Illinois
- University of Chicago Medical Center /ID# 271373 - Chicago
- Northwest Oncology & Hematology - Elk Grove Village /ID# 222818 - Elk Grove Village
- Loyola University Medical Ctr /ID# 219048 - Maywood
Georgia
- Augusta University Georgia Cancer Center /ID# 219051 - Augusta
- Columbus Regional Research Institute /ID# 224410 - Columbus
Louisiana
- Tulane Medical Center - New Orleans /ID# 222940 - New Orleans
- Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 222777 - New Orleans
Arizona
- Ironwood Cancer & Res Ctr /ID# 222162 - Chandler
Arkansas
- Highlands Oncology Group, PA /ID# 221826 - Springdale
Colorado
- St. Mary's Hospital Regional Cancer Center /ID# 224229 - Grand Junction
Indiana
- Indiana Blood & Marrow Transpl /ID# 221587 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04468984
The ClinicalTrials.gov registry entry for NCT04468984 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 931-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (65% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis (MF) appearing as the primary indexed condition, and to 3 interventions - of which Ruxolitinib is the first listed.
NCT04468984 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Georgia.
Frequently Asked Questions
What is clinical trial NCT04468984 about?
NCT04468984 is a clinical study titled "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis". Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best ava...
What is the current status of trial NCT04468984?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2020-08-31. Estimated completion is 2026-12.
What conditions does trial NCT04468984 study?
This clinical trial studies the following conditions: Myelofibrosis (MF).
What interventions are being tested in trial NCT04468984?
The interventions under investigation include: Ruxolitinib (DRUG), Navitoclax (DRUG), Best Available Therapy (BAT) (DRUG).
Who is sponsoring clinical trial NCT04468984?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04468984 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis (MF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
COMPLETED · Phase 3
-
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RECRUITING · Phase 1
-
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RECRUITING
-
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RECRUITING · Phase 2
-
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.